---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-031971"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:51:17.064233+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Reviva reports Q3 loss of $10.5M; Phase 3 brilaroxazine trial meets all endpoints

## Summary
- Phase 3 RECOVER trial met primary endpoint: 10.1-point PANSS reduction for 50 mg brilaroxazine vs placebo at week 4 (p<0.001).
- Net loss for Q3 2023 of $10.5M ($0.44/share) vs $3.5M loss ($0.18/share) in Q3 2022.
- Cash of $5.0M as of Sep 30, 2023, down from $18.5M at Dec 31, 2022.
- Anticipated milestones: OLE data Q4 2024; RECOVER-2 initiation Q1 2024; NDA submission 2025.

## SEC filing metadata
- accession: 0001437749-23-031971
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774923031971/0001437749-23-031971-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774923031971/rvph20231109c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-031971
- JSON: https://secwatch.observer/filing/0001437749-23-031971.json
- Plain text: https://secwatch.observer/filing/0001437749-23-031971.txt

## Key facts
- Earnings Releases
  REVIVA PHARMACEUTICALS HOLDINGS, INC. reported third quarter ended September 30, 2023 results: net income approximately $10.5 million, EPS ($0.44) per share.
  - Period: third quarter ended September 30, 2023
  - Net income: approximately $10.5 million
  - EPS: ($0.44) per share
  - Result: reported results
  source text: The Company reported a net loss of approximately $10.5 million, or ($0.44) per share, for the three months ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1742927/000143774923031971/0001437749-23-031971-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.